Aminophylline - Advanz Pharma

Aminophylline is used to widen the bronchi and reduce the amount of swelling and mucous in the lungs.

Slow intravenous injection
Severe acute asthma or acute exacerbation of COPD in patients not previously treated with theophylline, by slow intravenous injection over at least 20 minutes (with close monitoring):
• Child: 5 mg/kg (maximum per dose 500 mg), to be followed by intravenous infusion
• Adult: 250–500 mg (maximum per dose 5 mg/kg), to be followed by intravenous infusion.

Severe acute exacerbation of COPD in patients not previously treated with theophylline
• Adult: 250–500 mg (maximum per dose 5 mg/kg), to be followed by intravenous infusion.

By intravenous infusion
Severe acute asthma:
• Child under 12 years: 1 mg/kg/hour, adjusted according to plasma-theophylline concentration.
• Over 12 years: 500–700 mcg/kg/hour, adjusted according to plasma-theophylline concentration
• Elderly: 300 mcg/kg/hour, adjusted according to plasma–theophylline concentration.

Severe acute exacerbation of COPD by intravenous infusion:
• Adult: 500–700 mcg/kg/hour, adjusted according to plasma-theophylline concentration
• Elderly: 300 mcg/kg/hour, adjusted according to plasma-theophylline concentration.

By mouth using modified-release medicines
Chronic asthma:
• Child (body weight 40kg and above): 225 mg twice daily for 1 week, then increased if necessary to 450 mg twice daily, adjusted according to plasma-theophylline concentration.

Reversible airway obstruction:
• Adult (body weight 40kg and above): Initially 225 mg twice daily for 1 week, then increased if necessary to 450 mg twice daily, adjusted according to plasma theophylline concentration.

Aminophylline - Alliance Healthcare (Distribution) Ltd

Aminophylline is used to widen the bronchi and reduce the amount of swelling and mucous in the lungs.

Slow intravenous injection
Severe acute asthma or acute exacerbation of COPD in patients not previously treated with theophylline, by slow intravenous injection over at least 20 minutes (with close monitoring):
• Child: 5 mg/kg (maximum per dose 500 mg), to be followed by intravenous infusion
• Adult: 250–500 mg (maximum per dose 5 mg/kg), to be followed by intravenous infusion.

Severe acute exacerbation of COPD in patients not previously treated with theophylline
• Adult: 250–500 mg (maximum per dose 5 mg/kg), to be followed by intravenous infusion.

By intravenous infusion
Severe acute asthma:
• Child under 12 years: 1 mg/kg/hour, adjusted according to plasma-theophylline concentration.
• Over 12 years: 500–700 mcg/kg/hour, adjusted according to plasma-theophylline concentration
• Elderly: 300 mcg/kg/hour, adjusted according to plasma–theophylline concentration.

Severe acute exacerbation of COPD by intravenous infusion:
• Adult: 500–700 mcg/kg/hour, adjusted according to plasma-theophylline concentration
• Elderly: 300 mcg/kg/hour, adjusted according to plasma-theophylline concentration.

By mouth using modified-release medicines
Chronic asthma:
• Child (body weight 40kg and above): 225 mg twice daily for 1 week, then increased if necessary to 450 mg twice daily, adjusted according to plasma-theophylline concentration.

Reversible airway obstruction:
• Adult (body weight 40kg and above): Initially 225 mg twice daily for 1 week, then increased if necessary to 450 mg twice daily, adjusted according to plasma theophylline concentration.

Aminophylline - Hameln Pharma Ltd

Aminophylline is used to widen the bronchi and reduce the amount of swelling and mucous in the lungs.

Slow intravenous injection
Severe acute asthma or acute exacerbation of COPD in patients not previously treated with theophylline, by slow intravenous injection over at least 20 minutes (with close monitoring):
• Child: 5 mg/kg (maximum per dose 500 mg), to be followed by intravenous infusion
• Adult: 250–500 mg (maximum per dose 5 mg/kg), to be followed by intravenous infusion.

Severe acute exacerbation of COPD in patients not previously treated with theophylline
• Adult: 250–500 mg (maximum per dose 5 mg/kg), to be followed by intravenous infusion.

By intravenous infusion
Severe acute asthma:
• Child under 12 years: 1 mg/kg/hour, adjusted according to plasma-theophylline concentration.
• Over 12 years: 500–700 mcg/kg/hour, adjusted according to plasma-theophylline concentration
• Elderly: 300 mcg/kg/hour, adjusted according to plasma–theophylline concentration.

Severe acute exacerbation of COPD by intravenous infusion:
• Adult: 500–700 mcg/kg/hour, adjusted according to plasma-theophylline concentration
• Elderly: 300 mcg/kg/hour, adjusted according to plasma-theophylline concentration.

By mouth using modified-release medicines
Chronic asthma:
• Child (body weight 40kg and above): 225 mg twice daily for 1 week, then increased if necessary to 450 mg twice daily, adjusted according to plasma-theophylline concentration.

Reversible airway obstruction:
• Adult (body weight 40kg and above): Initially 225 mg twice daily for 1 week, then increased if necessary to 450 mg twice daily, adjusted according to plasma theophylline concentration.

Anoro Ellipta - Umeclidinium with vilanterol

Antimuscarinic bronchodilator with long-acting selective beta2 agonist.

• Adult over 18 years for maintenance treatment of COPD: by inhalation of powder, 1 inhalation, once daily.

Atectura Breezhaler - Indacaterol with mometasone furoate

Long-acting selective beta2 agonist with corticosteroid.

For prophylaxis of asthma
Atectura Breezhaler 125/62.5
Atectura Breezhaler 125/260
Atectura Breezhaler 125/127.5
Adult: one inhalation once daily.

Atimos Modulite - Formoterol (eformoterol) fumarate

Long-acting selective beta2 agonist.

Reversible airways obstruction in patients requiring long-term regular bronchodilator therapy
Nocturnal asthma in patients requiring long-term regular bronchodilator therapy
Prophylaxis of exercise-induced bronchospasm in patients requiring long-term regular bronchodilator therapy
Chronic asthma in patients who regularly use an inhaled corticosteroid
By inhalation of powder:
• Child 6-11 years: 12 mcg twice daily should be sufficient for the majority of children, particularly for younger age-groups. Higher doses should be used rarely, and only when control is not maintained on the lower dose.
• Child 12-17 years: 12 mcg twice daily. Dose may be increased in more severe airway obstruction to 24 mcg twice daily, which should be sufficient for the majority of children, particularly for younger age-groups. Higher doses should be used rarely, and only when control is not maintained on the lower dose.
• Adult: 12 mcg twice daily. Dose may be increased in more severe airway obstruction to 24 mcg twice daily.

By inhalation of aerosol:
• Child 12-17 years: 12 mcg twice daily. Dose may be increased in more severe airway obstruction to 24 mcg twice daily, which should be sufficient for the majority of children, particularly for younger age-groups. Higher doses should be used rarely, and only when control is not maintained on the lower dose.
• Adult: 12 mcg twice daily, dose may be increased in more severe airway obstruction; increased to 24 mcg twice daily.

COPD
By inhalation of powder
• Adult: 12 mcg twice daily

By inhalation of aerosol
• Adult: 12 mcg twice daily (maximum per dose 24 mcg). If required, additional doses up to a maximum of 48 mcg per day can be taken.

Atrovent - Ipratropium bromide

Antimuscarinic bronchodilator.

Reversible airway obstruction by inhalation of aerosol
• Child 1 month–5 years: 20 mcg, 3 times daily.
• Child 6–11 years: 20–40 mcg, 3 times daily.
• Over 12 years: 20–40 mcg, 3–4 times daily.

For reversible airways obstruction in COPD by inhalation of nebulised solution
• Adult: 250–500 mcg, 3–4 times daily.

For reversible airways obstruction in COPD by inhalation of aerosol
• Adult: 20–40 mcg, 3–4 times daily.

Severe or life-threatening acute asthma by inhalation of nebulised solution
• Child 1 month–11 years: 250 mcg, every 20–30 minutes, for the first two hours, then repeat every 4–6 hours, as required.
• Over 12 years: 500 mcg, every 4–6 hours, as required.

Acute bronchospasm by inhalation of nebulised solution
• Child 1 month–5 years: 125–250 mcg, maximum 1 mg daily.
• Child 6–11 years: 250 mcg, maximum 1 mg daily.
• Over 12 years: 500 mcg, repeated as necessary, usual maximum 2 mg daily. Doses higher than the recommended maximum can be given under medical supervision.

Rhinorrhoea associated with allergic and non-allergic rhinitis by intranasal administration
• Over 12 years: 2 sprays, 2–3 times/day into each nostril.

AVAX 50DL

A lightweight, inexpensive blood oxygen saturation and heart rate monitor. It can measure SpO2 between 35–99% with an accuracy of +/- 2%, and pulse between 30–240 BPM with an accuracy of +/-2 BPM.

Stockist: Amazon. 

Avenor - Salmeterol and fluticasone

For prophylaxis of asthma with Avenor® 25/125 by inhalation of aerosol
Child 12–17 years: 2 inhalations twice daily.
Adult: 2 inhalations twice daily.

For prophylaxis of asthma with Avenor® 25/250 by inhalation of aerosol
Child 12–17 years: 2 inhalations twice daily.
Adult: 2 inhalations twice daily.

For prophylaxis of asthma with Avenor® 25/50 by inhalation of aerosol
Child 4–17 years: 2 inhalations twice daily, reduced to 2 inhalations once daily, use reduced dose only if control maintained.
Adult: 2 inhalations twice daily, reduced to 2 inhalations once daily, use reduced dose only if control maintained.

Beclometasone (beclomethasone) dipropionate - Orion Pharma

For the prophylaxis of asthma by inhalation of powder
Child 5-11 years: 100–200 micrograms twice daily, dose to be adjusted as necessary.
Over 12 years: 200–400 micrograms twice daily; increased if necessary up to 800 micrograms twice daily, dose to be adjusted as necessary.

For the prophylaxis and treatment of allergic and vasomotor rhinitis by intranasal administration
• Over 6 years: 100 mcg twice daily, dose to be administered into each nostril. Maximum of 400 mcg per day. Reduce to 50 mcg twice daily if symptoms are controlled.